

# PNC's Corporate Healthcare Index

Second Quarter 2025




PNC's Corporate Healthcare Index (the "Index") is a tool, calculated quarterly, that examines the performance of—and trends within—the entire healthcare ecosystem. S&P launched the S&P 500 Healthcare Sector Index in 1996, but it is comprised of conventional healthcare entities in traditional subsegments. As healthcare becomes more consumer-centric, PNC's Index takes a modernized, non-traditional view of the healthcare landscape, tracking equity performance of the entire ecosystem based on a broad set of criteria.

Healthcare is being redefined and reshaped nearly every day in a variety of ways, as new entrants disrupt business models, retailers enter the ecosystem, and healthcare professionals search for new ways to improve the impact and efficiency of care delivery. It is the single, largest industry in the United States with an approximate spend of \$4.9T for 2023, nearly 18% of GDP.<sup>1</sup>

- **PNC's Corporate Healthcare Index** examines 40 of the top public companies driving healthcare industry activity within six key categories: Emerging Trends, Health Technology / IT, Payors, Pharmaceuticals & Life Sciences, Providers, and Supply Chain / OEM.
- The Index is calculated on a market capitalization-weighted basis for direct comparison with both the S&P 500 Index and the S&P 500 Healthcare Sector Index.
- Over the last quarter, the Index outperformed the S&P Healthcare Sector Index while underperforming the broader S&P 500. Performance was driven largely by gains among the Emerging Trends, Health Technology / IT, and Providers subsegments (see page 3).

## PNC's Corporate Healthcare Index<sup>2,3</sup>



## Market Commentary

### Healthcare Industry

Toward the start of 2025, the Administration announced sweeping tariffs for all US trading partners. The declaration invited competing opinions on the ultimate balance of price increases vs. domestic job creation. Regardless, market turmoil ensued—albeit briefly—before those tariffs were sidelined with the announcement of a 90-day pause to further negotiate. Equity markets have staged a significant rebound, though the pendulum may swing back following the end of the moratorium, now extended through August 1. While “tariff talk” has anchored discussions through Q2, many decision-makers remain in limbo, awaiting further clarity before instituting material change. To date, healthcare ecosystem impact has been nominal, primarily affecting some suppliers and group purchasing organizations.

However, the One Big Beautiful Bill Act (“OBBA” or the “Bill”) could have tremendous impact on the healthcare industry. Through enrollment and eligibility changes, site neutrality, and a Provider Tax freeze, among other provisions, the Bill aims to mitigate future federal spending for Medicaid. According to CMS estimates, Medicare spending is expected to increase 7.7% through 2025.<sup>1</sup> Meanwhile, federal Medicaid spend is set to slow while State-based expenditures have, and will likely continue, to increase.<sup>4</sup> Uncertainty persists, but an increase in the uninsured population is likely to drive a significant spike in uncompensated care, and reductions in clinical trial funding could slow progress in research if/when the Bill is passed. With more limited federal support, state policy will be paramount. Ostensibly, the OBBA will materially impact the healthcare industry for years to come, and, as a result of all the activity in DC, there were other notable themes influencing the industry:

- **Payor Vulnerability:** Payor stocks soared immediately following President Trump’s reelection last year, but a recent miss in earnings for one of the Big Five commercial insurers last quarter, proposed decreases in federal Medicaid spend growth, and recent exits from Medicare Advantage (“MA”) strategies have catalyzed consternation in the payor marketplace for the first time in a while. The “pay-vider” components of these insurers (Optum, Evernorth, etc.) have helped buoy revenue and earnings. Meanwhile, payor-provider tensions continue as major health systems, still at the epicenter of the healthcare ecosystem, continue to experience ramped up denials, and increasing prior authorization (“PA”) activity. Because payor output and performance tend to yield significant ripples throughout healthcare, the entire industry is closely monitoring broader and continued shifts within this sector.
- **HHS Regulations:** In response to industry and regulatory backlash, nearly 50 payors have agreed to ease PA requirements, per HHS’ latest stipulations (despite recent layoffs within the dept.). Although providers have broadly expressed content with this change, CMMI’s priorities remain unclear. Speculation is that HHS will likely follow MA trends and will begin eliminating social services / determinants of health, or perceived “perks,” that are covered by some Medicaid plans, impacting healthcare-adjacent services like non-emergent transportation and nutrition services.
- **Transaction Reticence Easing:** Lately, deal activity has picked up significantly across industries. Healthcare’s major contributions for Q2 are anchored by Hinge’s and Omada’s IPOs, as well as Ascension’s \$3.9B acquisition of AmSurg. Pent-up demand and dry powder abound still, but there is cautious optimism that these will ease over the rest of the year, particularly for those providers pursuing growth and margin via outpatient / specialty services. The question remains: **will healthcare entities continue to focus on cost and price today, or pivot towards growth for tomorrow?**

### Industry Subsectors

#### Emerging Trends:

- Hinge Health is off to a strong start, trading at 30%+ over its IPO pricing. Omada Health represents Q2’s other major IPO, though has fared worse, trading down about 25%<sup>2</sup>
- Hims & Hers share price tanked following Novo Nordisk’s termination of their GLP-1 partnership.<sup>3</sup> As reported previously, Hims & Hers has had ongoing disputes with other GLP-1 makers and mixed luck providing them to patients at reasonable cost
- To cut costs, employers are embracing Individual Coverage Health Reimbursement Arrangements (“ICHRA”). Previously, ICHRA primarily appealed to smaller companies looking to subsidize health benefits while managing costs, but many middle market companies are considering ICHRA as well.<sup>6</sup> Moreover, due to health cost inflation over the last several years, point solutions are making a comeback<sup>7</sup>
- While UNH and Amedisys work to close their pending deal, the DOJ has blocked the divestiture of certain home health assets to BrightSpring and The Pennant Group, citing the asset sales as inadequate remedy to antitrust concerns<sup>8</sup>
- 23andMe sold to Regeneron for \$256M via a bankruptcy auction<sup>9</sup>

#### Payors:

- Payors still grapple with MA, despite benchmark increases, and how to administer without compromising margins. Benefits have already been cut for cost control<sup>18</sup>
- MA Partnerships amongst payors and providers are still being formed. Scan and Sutter announce joint venture to begin in the Fall<sup>19</sup>
- Commercial insurers’ fight for market share rolls on as buyers shop for the best pricing (BCBSID cuts 10% of workforce after losing contracts to UHC and Molina)<sup>20</sup>
- Payor revenues have strengthened surrounding focus on “coding intensity” efforts<sup>21</sup>
- In the shadow of Medicaid growth cuts, Centene reported an increase in exchange membership of 29% for Q1,<sup>22</sup> while Aetna plans to exit exchanges by 2026<sup>23</sup>

#### Providers:

- Ascension’s \$3.9B acquisition of AmSurg is sparking improvement in the system’s margin projections, particularly as it refines its SAs at the same time.<sup>28</sup> Ascension has also purchased the remainder of Cedar Park Med Center to supplement its Central TX market<sup>29</sup>
- Welsh, Carson invests in Constitution Surgery Alliance with plans for significant expansion.<sup>30</sup> Expect others to tag along on broader ASC investment trend
- Major capital projects underway, albeit under heightened scrutiny, given uncertainty<sup>31</sup>
- Novant acquires 15 Imaging Centers<sup>32</sup> and Duke acquires CHS hospital for \$284MM<sup>33</sup>
- Competition for beds heats up in CON states, particularly NC, due to speed of population growth. Out of necessity, we may see CON repeal / reform take hold in some states<sup>34</sup>
- ABA / Behavioral Health continues to be an attractive investment thesis<sup>35</sup>

#### Health Technology / IT:

- Cyberattacks continue. Davita hit with ransomware attack,<sup>10</sup> and Oracle notifies its healthcare clients of another cybersecurity breach, piling on from the other incident reported in March<sup>11</sup>
- Digital Health investments are on the rise (again) after a bit of a lull in prior quarters, led by large funding rounds from later stage companies.<sup>12</sup> AMZN, along with major health systems, pledge a series of partnerships with digital health companies as well<sup>13</sup>
- Best Buy Health is restructuring and has sold Current Health, the nexus of its home health operation, back to its founder in a show of further retailer retrenchment from healthcare<sup>14</sup>
- As Millennials and Gen Z begin to utilize more healthcare services, a JD Power survey found that more than 65% favor paying with digital wallet technology (i.e., Apple Pay, Zelle, etc.). Companies like OnBe, Dash, and Verity are focusing solely on healthcare<sup>15</sup>
- AI pilots continue launch across accreditation, credentialing, and even claims appeals<sup>16</sup>
- Cigna rolls out a suite of cutting-edge tech tools to improve the member experience<sup>17</sup>

#### Pharmaceuticals & Life Sciences:

- Becton Dickinson announces biosciences and diagnostics division’s \$17.5B merger with Waters Corp. Expect this to be a point of inflection for further industry consolidation<sup>24</sup>
- Moody’s predicts that the Inflation Reduction Act’s changes to Medicare Part D benefits will negatively impact pharma’s bottom line, though likely offset by higher volumes<sup>25</sup>
- If drug prices increase due to tariff impact, 340B takes center stage again as hospitals and providers lobby for preservation of the program
- Medtronic and peers continue to refine portfolios, focusing on core operations and unlocking value within lucrative, specialty lines of business (e.g., MDT to spin off diabetes division)<sup>26</sup>
- After initial successes, Elon Musk’s Neuralink raises \$650M heading into clinical trials<sup>27</sup>

#### Supply Chain / OEM:

- As the Administration continues negotiating trade agreements with US trading partners, tariffs will continue to loom over all healthcare industry subsegments including providers, OEMs, Group Purchasing Organizations, etc. We are circumspect about murmurs that “rationing” may occur within care delivery due to ballooning costs, but ultimate tariff impacts have yet to be felt as the 90-day moratorium has been extended to 8/1<sup>36</sup>
- Continuing the tariff thread, several major companies, both in and out of the healthcare space, have all but torn up their guidance for 2025 and beyond<sup>37</sup>
- Axios reports that UPS has agreed to acquire Andlauer Healthcare Group, a Canadian provider of healthcare logistics and transportation services, for \$1.6B;<sup>38</sup> rival DHL has also announced \$2B of investments in healthcare logistics through 2030 to focus on cold storage and delivery<sup>39</sup>

PNC's Corporate Healthcare Index - Index Constituents and Periodic Return Data<sup>2,3</sup>

	Periodic Return Data as of End of Trading on 6/30/25						
	1-Month	3-Month	6-Month	1-Year	3-Year	5-Year	Year-to-Date
<b>S&amp;P 500 Index Value</b>	4.96%	10.57%	5.50%	13.63%	63.92%	100.14%	5.50%
<b>S&amp;P 500 Health Care Sector Index Value</b>	1.88%	(7.62%)	(2.01%)	(7.52%)	5.23%	34.66%	(2.01%)
<b>PNC's Corporate Healthcare Index Value</b>	5.67%	3.86%	0.08%	1.17%	67.10%	110.42%	0.08%

## Index Constituents:

## Emerging Trends

1. agilon health, inc.	3.60%	(46.88%)	21.05%	(64.83%)	(89.46%)	-	21.05%
2. Alphabet Inc.	2.61%	13.96%	(6.90%)	(3.25%)	61.73%	148.55%	(6.90%)
3. Amazon.com, Inc.	7.01%	15.31%	0.00%	13.53%	106.56%	59.05%	0.00%
4. AMN Healthcare Services, Inc.	(2.08%)	(15.49%)	(13.59%)	(59.65%)	(81.16%)	(54.31%)	(13.59%)
5. CVS Health Corporation	7.71%	1.82%	53.66%	16.80%	(25.56%)	6.17%	53.66%
6. Hinge Health, Inc.	33.24%	-	-	-	-	-	-
7. JPMorgan Chase & Co.	9.81%	18.19%	20.94%	43.34%	157.45%	208.22%	20.94%
8. Owens & Minor, Inc.	37.88%	0.78%	(30.37%)	(32.59%)	(71.07%)	19.42%	(30.37%)
9. Walgreens Boots Alliance, Inc.	2.04%	2.78%	23.04%	(5.08%)	(69.71%)	(72.92%)	23.04%
10. Walmart Inc.	(0.95%)	11.38%	8.22%	44.41%	141.27%	144.90%	8.22%

## Health Technology / IT

11. Oracle Corporation	32.08%	56.38%	31.20%	54.84%	212.91%	295.57%	31.20%
12. Salesforce, Inc.	2.76%	1.61%	(18.44%)	6.06%	65.23%	45.57%	(18.44%)
13. Teladoc Health, Inc.	25.87%	9.42%	(4.18%)	(10.94%)	(73.77%)	(95.44%)	(4.18%)
14. Veradigm Inc.	9.30%	7.80%	(51.79%)	(50.53%)	(68.31%)	(30.58%)	(51.79%)

## Payers

15. Centene Corporation	(3.83%)	(10.59%)	(10.40%)	(18.13%)	(35.85%)	(14.59%)	(10.40%)
16. The Cigna Group	4.40%	0.48%	19.71%	0.00%	25.45%	76.17%	19.71%
17. Elevance Health, Inc.	1.33%	(10.58%)	5.44%	(28.22%)	(19.40%)	47.90%	5.44%
18. Humana Inc.	4.87%	(7.60%)	(3.64%)	(34.57%)	(47.77%)	(36.95%)	(3.64%)
19. UnitedHealth Group Incorporated	3.33%	(40.44%)	(38.33%)	(38.74%)	(39.26%)	5.77%	(38.33%)

## Pharmaceuticals &amp; Life Sciences

20. Biogen Inc.	(3.24%)	(8.22%)	(17.87%)	(45.82%)	(38.42%)	(53.06%)	(17.87%)
21. Cencora, Inc.	2.96%	7.82%	33.46%	33.09%	111.94%	197.56%	33.46%
22. Eli Lilly and Company	5.67%	(5.62%)	0.98%	(13.90%)	140.43%	374.80%	0.98%
23. Johnson & Johnson	(1.58%)	(7.89%)	5.62%	4.51%	(13.95%)	8.62%	5.62%
24. Merck & Co., Inc.	3.02%	(11.81%)	(20.43%)	(36.06%)	(13.17%)	2.37%	(20.43%)
25. Moderna, Inc.	3.88%	(2.68%)	(33.65%)	(76.77%)	(80.69%)	(57.03%)	(33.65%)
26. Pfizer Inc.	3.19%	(4.34%)	(8.63%)	(13.37%)	(53.77%)	(25.87%)	(8.63%)
27. Roche Holding AG	(2.67%)	(11.05%)	1.14%	3.57%	(18.88%)	(21.30%)	1.14%
28. Thermo Fisher Scientific Inc.	0.66%	(18.52%)	(22.06%)	(26.68%)	(25.37%)	11.90%	(22.06%)

## Providers

29. HCA Healthcare, Inc.	0.45%	10.87%	27.64%	19.24%	127.95%	294.70%	27.64%
30. Surgery Partners, Inc.	(5.84%)	(6.40%)	5.01%	(6.56%)	(23.13%)	92.13%	5.01%
31. Tenet Healthcare Corporation	4.28%	30.86%	39.43%	32.30%	234.86%	871.84%	39.43%

## Supply Chain / OEM

32. Cardinal Health, Inc.	8.78%	21.94%	42.05%	70.87%	221.41%	221.90%	42.05%
33. DaVita Inc.	4.54%	(6.88%)	(4.75%)	2.80%	78.15%	80.00%	(4.75%)
34. GE HealthCare Technologies Inc.	5.00%	(8.23%)	(5.26%)	(4.94%)	-	-	(5.26%)
35. Hologic, Inc.	4.81%	5.49%	(9.61%)	(12.24%)	(5.97%)	14.32%	(9.61%)
36. McKesson Corporation	1.84%	8.88%	28.58%	25.47%	124.63%	377.63%	28.58%
37. Medtronic plc	5.05%	(2.99%)	9.13%	10.75%	(2.87%)	(4.94%)	9.13%
38. Molina Healthcare, Inc.	(2.34%)	(9.56%)	2.35%	0.20%	6.54%	67.38%	2.35%
39. Premier, Inc.	(4.57%)	13.74%	3.44%	17.46%	(38.54%)	(36.03%)	3.44%
40. Solventum Corporation	3.76%	(0.26%)	14.80%	43.42%	-	-	14.80%

Healthcare at PNC Overview

Contact Information

Healthcare at PNC by the Numbers<sup>40</sup>

**Gyasi Chisley**  
*Head of Corporate Healthcare*  
312.338.2257  
gyasi.chisley@pnc.com

**Chris Ditta, CFA**  
*VP, Corporate Healthcare*  
215.883.8937  
christopher.ditta@pnc.com

**Brian R. Kelly**  
*Head of PNC Healthcare*  
412.762.2976  
brian.r.kelly@pnc.com

**\$40B**  
*in Capital Commitments  
to Healthcare Companies Across the US*

**52,000+**  
*Healthcare Clients Served through PNC's  
Extensive Suite of Solutions*

**750+**  
*Relationships with  
Private Equity Firms*

**500+**  
*Employees Directly Serving  
Our Healthcare Clients*

**30+**  
*Years of Dedicated Sector Coverage via the  
PNC Healthcare Industry Vertical*

**\$13.3B**  
*Healthcare Client Assets Under  
Management (AUM)<sup>41</sup>*

Let's build your brilliant.



To learn more about how PNC Healthcare can deliver ideas, insights and solutions to help you move your business forward, contact your Relationship Manager or visit [pnc.com/healthcare](https://pnc.com/healthcare).

1. Centers for Medicare & Medicaid Services  
2. Share price data is sourced from S&P CapitalIQ as of July 1, 2025  
3. "PNC's Corporate Healthcare Index Value" is a weighted average of the constituents' share prices as of the end of trading on June 30, 2025. The Index is a market capitalization-weighted equity index. Rebalancing occurs on the last trading day of each fiscal quarter, most recently June 30, 2025. '-' is shown where there is insufficient share price history to calculate a percentage return over the specified time period.  
4. Pew: "The Share of State Budgets Spent on Medicaid Posts Largest Annual Increase in 20 Years" - June 16, 2025  
5. CNBC: "Novo Nordisk Ends Deal With Hims and Hers Over Sales of Wegovy Copycats; HIMS Drops 34%" - June 23, 2025  
6. Healthcare Dive: "ICHRA Adoption Grows as Congress Mulls Codifying the Coverage Into Law" - June 18, 2025  
7. Modern Healthcare: "Healthcare Point Solutions Make a Comeback With Employers" - May 13, 2025  
8. Hospice News: "DOJ Rejects Amedisys, UnitedHealth's Divestiture to BrightSpring, Pennant" - May 12, 2025  
9. Reuters: "Regeneron to Buy Bankrupt 23andMe, Vows Ethical Use of Customer DNA Data" - June 2, 2025  
10. Reuters: "Dialysis Firm DaVita Hit by Ransomware Attack, Says Patient Care Continues" - April 14, 2025  
11. Bloomberg: "Oracle Tells Clients of Second Recent Hack, Log-In Data Stolen" - April 2, 2025  
12. Modern Healthcare: "Digital Health Investments Rise, Deals Fall in 2025: Rock Health" - April 7, 2025  
13. Modern Healthcare: "Inside Amazon's Strategy to Partner With Digital Health Companies" - April 15, 2025  
14. Healthcare Dive: "Best Buy Divests Home Care Firm Current Health" - June 26, 2025  
15. JD Power: "Digital Wallet Satisfaction Study" - May 27, 2025  
16. BuiltIn: "AI in Healthcare: Uses, Examples and Benefits" - May 2, 2025  
17. Modern Healthcare: "Cigna Healthcare Debuts Array of Digital Tools to Assist Members" - June 12, 2025  
18. Better Medicare Alliance: "New Analysis Shows Impact of Recent Policymaking on Medicare Advantage Plans..." - October 21, 2024  
19. SCAN Health Press Release: "Sutter Health and SCAN Group Announce Strategic Collaboration" - April 10, 2025  
20. Modern Healthcare: "Blue Cross of Idaho Cuts 10% of Workforce After Contract Loss" - April 4, 2025  
21. Modern Healthcare: "Medicare Advantage Plans Reaped \$33B Extra From 'Coding Intensity'" - April 8, 2025  
22. Modern Healthcare: "Medicare, Exchanges Highlight Centene's First Quarter" - April 25, 2025  
23. Fierce Healthcare: "Aetna to Exit the ACA Exchanges in 2026" - May 1, 2026  
24. Reuters: "Waters to Buy Becton Unit in a \$17.5 Billion Deal Amid Tariff Pressures" - July 14, 2025  
25. Moody's Ratings: "Healthcare Quarterly - Implications of Medicaid and Medicare Changes" - April 2025  
26. Fierce Biotech: "Medtronic to Spin Out Diabetes Division as \$2.8B Independent Player" - May 21, 2025  
27. Reuters: "Musk's Neuralink Raises \$650 Million in Latest Funding as Clinical Trials Begin" - June 3, 2025  
28. Hospitalogy: "Ascension Seals the Deal" - June 24, 2025  
29. Ascension Press Release: "Ascension Seton to Take Full Ownership of Cedar Park Medical Center..." - April 15, 2025  
30. WCAS Press Release: "Constitution Surgery Alliance Announces Strategic Growth Investment from Welsh, Cason, Anderson & Stowe" - June 16, 2025  
31. Modern Healthcare: "Where Systems' \$1B+ Projects Stand Amid Market Uncertainty" - June 13, 2025  
32. The Charlotte Observer: "Novant Health Acquires OrthoCarolina Locations in Charlotte and Triad Regions" - April 1, 2025  
33. Healthcare Finance: "Duke Buys CHS Hospital for \$284 Million" - April 8, 2025  
34. Modern Healthcare: "Hospital Competition Heats Up as Capacity Wanes" - April 24, 2025  
35. Harris Williams: "Behavioral Health: Greater Need for Care, Rising M&A Momentum" - May 14, 2025  
36. Modern Healthcare: "Tariffs May Force Hospitals to Ration Supplies and Cut Services" - April 8, 2025  
37. The Wall Street Journal: "Corporate Giants Shred Outlooks Over Tariff Uncertainty" - April 24, 2025  
38. Axios: "\$1.6B UPS Deal Taps Lucrative Medical Shipment Market" - April 25, 2025  
39. Supply Chain 24/7: "DHL Plans \$2 Billion Investment to Grow Healthcare Logistics" - April 8, 2025  
40. Data as of June 30, 2025  
41. "Healthcare Client Assets Under Management" represents assets managed by PNC Bank, NA and PNC Capital Advisors, LLC, an SEC-registered investment adviser and wholly-owned subsidiary of PNC Bank

PNC and PNC Bank are registered marks. Brilliantly Boring Since 1865 is a service mark of The PNC Financial Services Group, Inc. ("PNC").

This newsletter, including the Index was prepared for general information purposes only and is not intended as legal, tax or accounting advice or as recommendations to engage in any specific transaction, including with respect to any securities of PNC, and does not purport to be comprehensive. Under no circumstances should any information contained in this newsletter, including the Index, be used or considered as an offer or commitment, or a solicitation of an offer or commitment, to participate in any particular transaction or strategy. Opinions and forecasts expressed herein are subject to change without notice. Relevant information was obtained from sources deemed reliable. Such information is not guaranteed as to its accuracy. Any reliance upon any such information is solely and exclusively at your own risk. Please consult your own counsel, accountant, or other investment professional to discuss, or tailor a financial plan to, your specific situation. Neither PNC Bank nor any other subsidiary of The PNC Financial Services Group, Inc., will be responsible for any consequences of reliance upon any opinion or statement contained here, or any omission.

©2025 The PNC Financial Services Group, Inc. All rights reserved.